Ponatinib is a tyrosine kinase inhibitor (TKI) specifically designed to target the BCR-ABL protein, which is produced by the Philadelphia chromosome abnormality. This protein is a key driver in certain types of blood cancers, including chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL).
